Nasdaq · Healthcare
Neuphoria Therapeutics Inc. (NEUP)
As-reported financials and recent SEC filings for Neuphoria Therapeutics Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$15.6M
Net income
$-369,632
Net margin
-2.4%
Diluted EPS
$-0.23
ROE
-1.9%
P/E (TTM)
—
Market cap
—
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2024 | FY2022 | FY2022 |
|---|---|---|---|---|---|
| Revenue | $15.6M | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | $-1.1M | $-17.9M | $-22.0M | — | — |
| Net income | $-369,632 | $-15.5M | $-21.4M | — | — |
| Diluted EPS | $-0.23 | $-9.31 | $-17.65 | — | — |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
8-K2026-05-26
View on EDGAR →10-Q2026-05-15
View on EDGAR →10-Q2026-02-17
View on EDGAR →SCHEDULE 13G/A2026-02-06
View on EDGAR →42026-01-21
View on EDGAR →42026-01-21
View on EDGAR →42026-01-21
View on EDGAR →42026-01-21
View on EDGAR →Largest Healthcare peers
Go deeper on NEUP
Search Neuphoria Therapeutics Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.